The IDH1 mutation rate was higher in NI subgroup II (82%) than NI subgroup I (36%), IDH1 mutation dramatically indicated the outcome of glioma patients, so the distinction in IDH1 mutation between two cluster subgroups may contribute to the prognosis of glioma. Here, IDH1 is linked to central nervous system cancer.